IS1822B - Glýkósamstæður, lyf sem innihalda þær, og notkun glýkósamstæðnanna við framleiðslu lyfja - Google Patents

Glýkósamstæður, lyf sem innihalda þær, og notkun glýkósamstæðnanna við framleiðslu lyfja

Info

Publication number
IS1822B
IS1822B IS4562A IS4562A IS1822B IS 1822 B IS1822 B IS 1822B IS 4562 A IS4562 A IS 4562A IS 4562 A IS4562 A IS 4562A IS 1822 B IS1822 B IS 1822B
Authority
IS
Iceland
Prior art keywords
glycosides
drugs
manufacture
drugs containing
cytostatics
Prior art date
Application number
IS4562A
Other languages
English (en)
Other versions
IS4562A (is
Inventor
Lerchen Hans-Georg
Von Dem Bruch Karsten
Petersen Uwe
Baumgarten Jörg
Piel Norbert
Antonicek Horst-Peter
Weichel Walter
Sperzel Michael
Dieter Bremm Klaus
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of IS4562A publication Critical patent/IS4562A/is
Publication of IS1822B publication Critical patent/IS1822B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Steroid Compounds (AREA)
IS4562A 1995-04-04 1997-09-18 Glýkósamstæður, lyf sem innihalda þær, og notkun glýkósamstæðnanna við framleiðslu lyfja IS1822B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (de) 1995-04-04 1996-03-22 Kohlenhydratmodifizierte cytostatika

Publications (2)

Publication Number Publication Date
IS4562A IS4562A (is) 1997-09-18
IS1822B true IS1822B (is) 2002-10-01

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4562A IS1822B (is) 1995-04-04 1997-09-18 Glýkósamstæður, lyf sem innihalda þær, og notkun glýkósamstæðnanna við framleiðslu lyfja

Country Status (27)

Country Link
US (1) US6271342B1 (is)
EP (1) EP0819135B1 (is)
JP (1) JPH11502860A (is)
KR (1) KR19980703591A (is)
CN (1) CN1185786A (is)
AT (1) ATE186738T1 (is)
AU (1) AU713466B2 (is)
BG (1) BG63048B1 (is)
BR (1) BR9604825A (is)
CA (1) CA2217164A1 (is)
CZ (1) CZ291098B6 (is)
DE (2) DE19512484A1 (is)
DK (1) DK0819135T3 (is)
EE (1) EE03619B1 (is)
ES (1) ES2140078T3 (is)
GR (1) GR3032605T3 (is)
HU (1) HUP9800513A3 (is)
IS (1) IS1822B (is)
MX (1) MX9707613A (is)
NO (1) NO974564L (is)
NZ (1) NZ305855A (is)
PL (1) PL183574B1 (is)
RU (1) RU2170234C2 (is)
SK (1) SK281785B6 (is)
TW (1) TW384290B (is)
UA (1) UA61054C2 (is)
WO (1) WO1996031532A1 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934329T3 (da) * 1996-09-30 2002-04-08 Bayer Ag Glycokonjugater af modificerede camptothecinderivater (20-O-binding)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
JP4669607B2 (ja) 1997-09-15 2011-04-13 ザ プロクター アンド ギャンブル カンパニー 抗微生物キノロン類、その組成物およびその使用
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
WO2003040093A2 (de) * 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopencodierte affinitätsmarker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
DK2001862T3 (da) 2006-03-28 2011-08-08 Warner Chilcott Co Llc Malatsalte og polymorfe af (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyklopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolincarboxylsyre
CA2647457C (en) 2006-03-28 2011-05-24 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
WO2007110835A2 (en) 2006-03-28 2007-10-04 The Procter & Gamble Company A coupling process for preparing quinolone intermediates
EP3242883A4 (en) * 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
JP6949732B2 (ja) 2015-11-25 2021-10-13 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自壊性基を含む複合体及びそれに関連した方法
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
AU2019266406A1 (en) 2018-05-09 2020-11-26 Ligachem Biosciences Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
ATE106898T1 (de) * 1987-03-26 1994-06-15 Neorx Corp Metall-radionuklid-markierte proteine und glykoproteine zur diagnose und therapie.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6075121A (en) 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
EP0545198B1 (de) 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptide mit insulinartiger Wirkung
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
FI933472A (fi) 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
DE59603678D1 (de) 1999-12-23
AU5397696A (en) 1996-10-23
WO1996031532A1 (de) 1996-10-10
EP0819135A1 (de) 1998-01-21
EP0819135B1 (de) 1999-11-17
UA61054C2 (en) 2003-11-17
SK134597A3 (en) 1998-05-06
MX9707613A (es) 1997-12-31
EE9700258A (et) 1998-04-15
CZ291098B6 (cs) 2002-12-11
SK281785B6 (sk) 2001-07-10
ATE186738T1 (de) 1999-12-15
EE03619B1 (et) 2002-02-15
BG101892A (en) 1998-05-29
AU713466B2 (en) 1999-12-02
BG63048B1 (bg) 2001-02-28
NO974564D0 (no) 1997-10-02
ES2140078T3 (es) 2000-02-16
HUP9800513A3 (en) 1998-09-28
DE19512484A1 (de) 1996-10-17
PL183574B1 (pl) 2002-06-28
RU2170234C2 (ru) 2001-07-10
CZ314397A3 (cs) 1998-01-14
PL322681A1 (en) 1998-02-16
TW384290B (en) 2000-03-11
KR19980703591A (ko) 1998-11-05
US6271342B1 (en) 2001-08-07
IS4562A (is) 1997-09-18
GR3032605T3 (en) 2000-05-31
NZ305855A (en) 1999-11-29
DK0819135T3 (da) 2000-05-08
BR9604825A (pt) 1999-01-05
JPH11502860A (ja) 1999-03-09
CN1185786A (zh) 1998-06-24
CA2217164A1 (en) 1996-10-10
NO974564L (no) 1997-11-25
HUP9800513A2 (hu) 1998-06-29

Similar Documents

Publication Publication Date Title
IS1822B (is) Glýkósamstæður, lyf sem innihalda þær, og notkun glýkósamstæðnanna við framleiðslu lyfja
TR199802423T2 (xx) Konsantre antikor terkibi.
DE69738961D1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
AP1703A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
TR200100054T2 (tr) Paroksetin metansülfonat
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
AU569624B2 (en) Avermectin and milbermycin 13-keto, 13-imino and 13-amino derivatives
BR9812182A (pt) Cloreto de n,n-bis(fenilcarbamoilmetil) dimetilamÈnio e seus derivados no tratamento da dor
CA2136841A1 (en) Novel Piperidyl Amides, Sulfonamides and Sulfoxamides as Inhibitors of Cholesterol Biosynthesis
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
EP0609292A4 (en) Soluble variants of type i membrane proteins, and methods of using them.
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
NO885406D0 (no) Fremgangsmaate for fremstilling av 4-heteroaryl-1,3-benzodiazepiner og 2-substituerte-alfa-(hetero-aryl)benzenetanaminer og anvendelse derav som medikamenter.
AU632313B2 (en) New platinum complexes, their preparation and pharmaceutical compositions which contain them
RU95105341A (ru) Водка "презент"
YU53596A (sh) Citostatici modifikovani sa ugljenim hidratima
AU1877488A (en) Phospholipid conjugates, protein conjugates, and their preparation
FI940822A (fi) Foerfarande foer mikrobiologisk rening av material, som innehaoller skadliga aemnen
OA07948A (en) Novel triazolyl-substituted propane derivatives, their preparation and pharmaceutical compositions containing them.
NO830234L (no) Daunorubicin- og doxorubicinanaloger, deres fremstilling og bruk.
IT8720179A0 (it) 2-sulfinil-acetil-1,3-tiazolidine, loro preparazione e composizioni farmaceutiche.